Citigroup Inc. Acquires 42,517 Shares of Catalent, Inc. (NYSE:CTLT)

Citigroup Inc. grew its holdings in Catalent, Inc. (NYSE:CTLT) by 26.2% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 204,923 shares of the company’s stock after purchasing an additional 42,517 shares during the quarter. Citigroup Inc.’s holdings in Catalent were worth $12,412,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent in the second quarter worth $42,000. Sentry Investment Management LLC bought a new stake in shares of Catalent during the 3rd quarter worth about $53,000. Longfellow Investment Management Co. LLC increased its holdings in shares of Catalent by 45.7% during the 2nd quarter. Longfellow Investment Management Co. LLC now owns 972 shares of the company’s stock valued at $55,000 after acquiring an additional 305 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Catalent by 25.9% in the 2nd quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock valued at $58,000 after acquiring an additional 212 shares in the last quarter. Finally, Intact Investment Management Inc. acquired a new stake in Catalent in the 3rd quarter worth approximately $73,000.

Insiders Place Their Bets

In other Catalent news, Director Michelle R. Ryan sold 2,800 shares of Catalent stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total transaction of $167,160.00. Following the sale, the director now directly owns 10,835 shares of the company’s stock, valued at approximately $646,849.50. The trade was a 20.54 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Mcerlane sold 1,994 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the completion of the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at approximately $2,177,150.88. The trade was a 5.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock worth $305,931 over the last 90 days. Corporate insiders own 0.31% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have commented on CTLT. Robert W. Baird reiterated a “neutral” rating and set a $63.50 price target on shares of Catalent in a report on Tuesday, September 24th. William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. Baird R W downgraded Catalent from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Finally, StockNews.com cut Catalent from a “hold” rating to a “sell” rating in a research report on Friday, November 22nd. One analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. Based on data from MarketBeat.com, Catalent has a consensus rating of “Hold” and an average target price of $63.40.

Catalent Stock Up 0.4 %

NYSE CTLT opened at $61.00 on Friday. Catalent, Inc. has a twelve month low of $36.74 and a twelve month high of $61.50. The stock has a market cap of $11.07 billion, a PE ratio of -26.99, a PEG ratio of 2.44 and a beta of 1.16. The firm has a 50-day simple moving average of $59.86 and a 200 day simple moving average of $58.41. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.96 and a current ratio of 2.51.

Catalent (NYSE:CTLT) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.18). The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. Catalent’s revenue for the quarter was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.10) EPS. On average, research analysts forecast that Catalent, Inc. will post 0.84 EPS for the current year.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.